1. Home
  2. NAT vs ABUS Comparison

NAT vs ABUS Comparison

Compare NAT & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nordic American Tankers Limited

NAT

Nordic American Tankers Limited

HOLD

Current Price

$5.48

Market Cap

914.8M

ML Signal

HOLD

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

HOLD

Current Price

$4.25

Market Cap

848.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NAT
ABUS
Founded
1995
2005
Country
Bermuda
United States
Employees
N/A
19
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
914.8M
848.8M
IPO Year
1997
2008

Fundamental Metrics

Financial Performance
Metric
NAT
ABUS
Price
$5.48
$4.25
Analyst Decision
Sell
Strong Buy
Analyst Count
2
1
Target Price
$4.00
$5.00
AVG Volume (30 Days)
3.7M
1.6M
Earning Date
05-28-2026
05-14-2026
Dividend Yield
8.50%
N/A
EPS Growth
N/A
55.26
EPS
N/A
0.87
Revenue
N/A
$14,083,000.00
Revenue This Year
$77.72
N/A
Revenue Next Year
N/A
$239.71
P/E Ratio
$525.49
$4.95
Revenue Growth
N/A
128.21
52 Week Low
$2.55
$3.04
52 Week High
$6.34
$5.10

Technical Indicators

Market Signals
Indicator
NAT
ABUS
Relative Strength Index (RSI) 42.56 45.31
Support Level $5.39 $4.17
Resistance Level $6.30 $4.62
Average True Range (ATR) 0.20 0.16
MACD -0.04 -0.00
Stochastic Oscillator 12.70 46.23

Price Performance

Historical Comparison
NAT
ABUS

About NAT Nordic American Tankers Limited

Nordic American Tankers Ltd owns and operates double-hull crude oil tankers. It is an international tanker company that owns double-hull Suezmax tankers. It operates vessels in the spot market or on spot market-related charters according to cooperative arrangements with third parties. The company's fleet consists of crude oil tankers, and all of its vessels are employed in the spot market. The company has only one type of vessel - Suezmax crude oil tankers. It operates in markets that are very competitive and based mainly on supply and demand.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: